1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Review Pathways

Priority Reviews At US FDA: From Third Quarter Spikes To A Third Quarter Trough

 
• By Michael Cipriano

Priority review announcements saw significant dip in third quarter 2018, while they usually experience a spike during the period; breakthrough therapy designations remained in double digits.

group of businessman in black suit and holding red arrow down graph

Priority review designation announcements regarding applications pending at the US FDA have generally spiked in the third quarter over the last several years, with 2016 being the exception. But not only have they failed to peak in third quarter of 2018; it looks like the three-month stretch will prove to be a notable trough.

After achieving respective totals of at least 21 and 28 in the first and second quarters of this year, sponsors...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Review Pathways

More from Pathways & Standards

US FDA Skips User Fee Increase For More Staff Amid Exodus, Hiring Difficulties

 
• By Derrick Gingery

A calculation used to determine whether the FDA has the staff to handle its workload also was not included in the description of prescription drug user fee calculations.

England: Pharma Firms To Benefit From Parallel HTA And Regulatory Pathway

 
• By Eliza Slawther

The UK drug regulator and England’s health technology assessment agency have joined forces under an information sharing agreement, aimed at accelerating patient access to newly approved medicines by three to six months.

August Brings Fresh Faces And Tough Calls To US FDA User Fee Calendar

 
• By Bridget Silverman

The FDA could act on 17 applications, including 10 novel agents, during August. Only one would be a second-cycle review.